Pheochromocytoma masked by mutation in the TH gene by Abid, Karim et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Pheochromocytoma masked by mutation in the TH gene
Abid, Karim; Afshar, Katayoun; Fontana, Enzo; Ducry, Julien; Rotman, Samuel; Stauffer, Edouard;
Fellmann, Florence; Tschopp, Oliver; Bhuiyan, Zahurul A; Grouzmann, Eric
DOI: https://doi.org/10.1373/clinchem.2015.248443
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-124864
Published Version
Originally published at:
Abid, Karim; Afshar, Katayoun; Fontana, Enzo; Ducry, Julien; Rotman, Samuel; Stauffer, Edouard;
Fellmann, Florence; Tschopp, Oliver; Bhuiyan, Zahurul A; Grouzmann, Eric (2016). Pheochromocytoma
masked by mutation in the TH gene. Clinical Chemistry, 62(7):924-928.
DOI: https://doi.org/10.1373/clinchem.2015.248443
Pheochromocytoma Masked by Mutation in the
TH Gene
Karim Abid,1† Katayoun Afshar,2† Enzo Fontana,3 Julien Ducry,3 Samuel Rotman,4 Edouard Stauffer,5
Florence Fellmann,6 Oliver Tschopp,7 Zahurul A. Bhuiyan,2† and Eric Grouzmann1*†
CASE DESCRIPTION
A 51-year-old woman consulting within the framework
of investigation for abdominal discomfort, nausea, and
vomiting underwent a computed tomography examination
that revealed a well-delimited right adrenal heterogeneous
mass measuring 8.2  8.3 cm with a native density of 40
Hounsfield units (HU)8. An 18F-deoxyglucose positron
emission tomography scan showed a hypercaptation on the
adrenal tumorof 7.4SUVmax.Apart from these symptoms,
the patient had no other complaint. Familial history was
unremarkable. On examination, the patient was in good
physical condition, arterial blood pressure was 136/85
mmHg, heart rate at 74 bpm.
The measurement of plasma renin activity and
aldosterone and the results of a 1-mg overnight dexa-
methasone suppression test ruled out primary hyper-
aldosteronism and Cushing syndrome. Catecholamine
and metanephrine concentrations in multiple blood and
urine samples were consistently within the reference in-
terval and not compatible with the diagnosis of a pheo-
chromocytoma (Table 1).
Because the adrenal mass was not hormonally active,
its surgical resection was performed without preoperative
care. The removal of a mass weighing 356 g in the right
adrenal gland was performed by open laparotomy.
Histopathological analysis of tissue sections of the
adrenal mass yielded an unexpected result: a pheochro-
mocytoma was diagnosed on the basis of typical well-
arranged nests called zellballen. This encapsulated adre-
nal tumor exhibits a low proliferation index (MIB-1,
1%–2%; 1 mitosis/high power field) without vascular
invasion. Immunohistochemistry of the tumor sections
revealed its neuroendocrine feature, with cells highly ex-
pressing CD56, chromogranin A, NSE, synaptophysin,
and vimentin. Unfortunately, blood samples obtained
before surgery were collected on heparin-coated tubes
precluding serum chromogranin A assay. Because the un-
usual presentation of a “non–catecholamine-secreting
pheochromocytoma” was in complete contradiction with
the biochemical feature expected for these tumors, we
studied the intratumoral protein expression of the main
enzymes involved in catecholamine synthesis by means of
immunohistochemistry on paraffin-embedded sections of
the tumor biopsy. Tyrosine hydroxylase (TH) was not ex-
pressed in tumor tissue compared to normal adrenal gland
medulla (Fig. 1 upper panel). Dopamine -hydroxylase
(DBH) and phenylethanolamine-N-methyl transferase
(PNMT) protein expressions were lower in the tumor than
in the adrenal medulla control, but the cells were clearly
stained (Fig. 1 middle and lower panels). The TH (tyrosine
hydroxylase)9 gene expression was approximately 20-fold
lower in this tumor than in the adrenal pheochromo-
cytoma (P  0.016), whereas expressions for DBH
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QUESTIONS TO CONSIDER
1. How can one define an adrenal pheochromocytoma that
is unable to secrete catecholamines?
2. What alternative may be proposed to monitor a non–
catecholamine-secreting pheochromocytoma?
3. How can one monitor for a possible relapse of a pheo-
chromocytoma for this patient?
4. Are special measures needed preoperatively before
removal of a non–catecholamine-producing adrenal
pheochromocytoma?
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(dopamine beta-hydroxylase) and PNMT (phenyle-
thanolamine N-methyltransferase) were unchanged
(P  0.29 and P  0.67, respectively). Routine blood
DNA analyses of the most common genes associated with a
familial risk for a pheochromocytoma, SDHB (succinate
dehydrogenase complex iron sulfur subunitB),SDHD (suc-
cinate dehydrogenase complex subunit D), VHL (von
Hippel-Lindau tumor suppressor), and RET (ret proto-
oncogene), were performed and revealed no mutations.
To investigate the molecular mechanism associated
with the absence of expression ofTH, the sequence of the
coding exons and the exon–intron boundaries of TH
were analyzed using the DNA from both blood lympho-
cytes and tumoral tissue of the patient (Fig. 1A and B).
Sequencing of TH in the tumor tissue uncovered a ho-
mo/hemizygous mutation, c.669 5 GC, in the exon
5/intron 5 junction of TH (Fig. 1B). The genomic loca-
tion of this mutation is at Chr11: 2189316 (http://
exac.broadinstitute.org/). This mutation has also been
detected in the DNA from the lymphocytes, but only in
the heterozygous state. This mutation was located in the
conserved region for RNA splicing (donor site), at the 3-
junction of exon and intron 5, and was likely to affect
RNA splicing efficiency.
CASE DISCUSSION
Pheochromocytomas are tumors of the adrenal medulla
that produce and usually secrete large amounts of cat-
echolamines often associated with high fatality rates
when undiagnosed (1 ). The usual recommendations for
assessing a hormonally active pheochromocytoma rely on
the measurement of metanephrines, the results of which
have high diagnostic sensitivity (1 ). Therefore, a negative
result allows excluding a pheochromocytoma with a high
level of confidence. When metanephrines are positive,
imaging studies must be used to locate the tumor, and pre-
medication with  and  adrenergic blockers is mandatory
Table 1. Concentrations of renin, aldosterone, cortisol, catecholamine, and their metabolites in urine and plasma found
in the patient.a
Concentration
Reference interval43 Days before surgery 32 Days postsurgery
Plasma catecholamines, nmol/L
Norepinephrine 3.11 NDb 0.64–6.55
Epinephrine 0.11 ND 0.02–1.23
Dopamine 0.02 ND 0.01–0.38
Plasma free metanephrines, nmol/L
Normetanephrine 0.47 0.28 0.04–1.39
Metanephrine 0.19 0.05 0.03–0.85
Methoxytyramine 0.01 0.01 <0.06
Plasma total metanephrines, nmol/L
Normetanephrine 5.67 7.83 2.14–36.65
Metanephrine 2.86 0.32 0.66–13.45
Methoxytyramine 1.4 0.58 0.59–4.19
Urine metanephrines, nmol/24 h
Normetanephrine 1657 ND <3800
Metanephrine 750 ND <1880
Methoxytyramine 4546 ND <1900
Plasma renin activity, ng  mL−1  h−1 0.3 ND 0.2–2.8
Plasma aldosterone, pg/mL 82 ND 42–202
Plasma cortisol, nmol/L 14 ND <138
a Themeasurementswere performed inplasmaandurine43days before (left column) and32days after (right column) the removal of the pheochromocytoma. All concentrationswere
within the normal range. Plasma aldosterone was determined by RIA (ALDO-RIACT, Cisbio Bioassays) and plasma renin activity using an RIA kit (DiaSorin). Plasma cortisol concen-
trations were determined on a Cobas Elecsys 2010 E170 analyzer (Roche Diagnostics). Plasma catecholamines and metanephrines were quantiﬁed with the patient in a supine
position after a 20-min rest by liquid chromatography tandem mass spectrometry and urine metanephrine by liquid chromatography coupled to electrochemical detection.
Reference intervals for bioamines have been published previously [Grouzmann et al. (10 )].
b ND, not done.
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to prevent hypertensive crises during surgical removal of the
tumor and fluid correction to prevent postsurgical hypoten-
sion (1 ). Finally, the tumor is definitively confirmed to be
a pheochromocytoma based on histologic analysis of the
tumor by an experienced pathologist and the expression
of neuroendocrine markers (1 ). There are circumstances
in which an adrenal mass is fortuitously found during
radiological examination of a patient in the absence of
symptoms or clinical signs suggestive of a pheochromo-
cytoma, possibly due to a high tumor rate of catechol-
amine metabolism or tachyphylaxia (2, 3 ). Mannelli et
al. found in a retrospective study conducted on 298 Ital-
ian patients affected by pheochromocytomas/paragan-
gliomas that 11.2% of the tumors were incidentally di-
agnosed, and among these, 62.5% of patients were
normotensive (3 ). The most dreaded presentation of
pheochromocytoma occurs in an asymptomatic patient
undergoing a procedure such as a surgical intervention
when a fortuitous adrenal mass has been discovered (4 ).
In these situations, mortality rates as high as 80% have
been reported owing to massive secretion of cat-
echolamines, leading to paroxysmal hypertensive crises
and multiorgan failure. Paragangliomas are extra-adrenal
chromaffin tumors that can be either sympathetic or para-
sympathetic. Most of these are catecholamine-secreting tu-
mors and primarily located in the abdomen (more rarely in
the chest) in the extraadrenal paraganglia, whereas the re-
mainder are generally non–catecholamine secreting and
mostly located in the head and neck paraganglia (5).How-
ever, metanephrine measurements are warranted to assess/
exclude their hormonal activity. The prevalence of these
adrenal incidentalomas increases with age, from 1% to
7% between 30 and 70 years of age (6).
RESOLUTION OF THE CASE
To further characterize the consequence of the c.669 
5GC mutation, sequence analysis of the cDNA gener-
ated from the tumor tissue was performed. The sequence
of the cDNA revealed that in TH from the tumor tissue a
cryptic donor splice site, c.669  8_9 GT was used for
mRNA splicing rather than the usual c.669  1_2 GT.
As a consequence, 7 nucleotides (GTGACTG) from in-
Fig. 1. Immunohistochemical studies of TH in the patient tumor contrasting with the expression of DBH and PNMT and genetic
analysis of TH in blood and pheochromocytoma.
Upper panel shows the patient tumor, right panel staining with a healthy adrenal gland as a positive control. TH protein expression is not
present in the tumor, whereas the adrenal control is producing TH. TH is the rate-limiting step in catecholamine synthesis involved in the
hydroxylation of L-tyrosine to 3,4-dihydroxy phenylalanine (DOPA). DOPA is decarboxylated to dopamine by L-aromatic amino acid decarbox-
ylase. Dopamine is hydroxylated into norepinephrine by dopamine-hydroxylase (DBH). PhenylethanolamineN-methyl transferase (PNMT),
an enzyme localized in adrenal chromafﬁn cells and pheochromocytes, leads to the methylation onto the amino group of norepinephrine to
produce epinephrine. Magniﬁcation for TH and DBH: 200× and 400× for PNMT. Arrows indicate adrenal medulla tissue and arrowheads
adrenal cortex section. Antibodies are described in Grouzmann et al. (2 ) and anti-PNMT antibody was purchased from Protos (Protos Biotech
Corp). (A) and (B) Nucleotide sequences of the exon 5 and intron 5 junction of the TH gene (NM_199292; ENST00000381178). The heterozy-
gous mutation c.669 + 5G>C (downward arrow) is observed in the exon 5–intron 5 junction (leftward dashed arrow) in lymphocyte-derived
DNA (A), while the mutation is homo/hemizygous (arrow marked) in tumor DNA (B). (C), cDNA from the tumor shows incorporation of seven
intronic nucleotides “GTGACTG” (in bold) in the cDNA. (D) Presence of a heterozygous SNP in the c.1239 position (downward arrow) in exon 12
of TH from the tumor, which is 2364 bp downstream of the mutation detected in the patient.
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tron 5 were incorporated into the new cDNA (Fig. 1C),
resulting in a frameshift in the amino acids with a prema-
ture stop codon (p.Gly223Valfs*18). Normal TH pro-
tein contains 528 amino acids, and in the tumor tissue
the putative TH protein had only 223 N-terminal amino
acids followed by a frameshift and premature truncation
(Fig. 1C).When the corresponding DNA sequence from
blood cells was investigated, the same mutation was
observed in a heterozygous state (Fig. 1A), indicating
that a second mutation, leading to homo/hemizygosity
for the c.669  5GC mutation, took place in the
early stages of tumor development. In the tumor
DNA, we also observed a heterozygous polymorphism
in exon 12 of TH, 2364-bp downstream of the muta-
tion (Fig. 1D).
From the genomic perspective, this patient had a
heterozygous germline mutation in TH, which turned
homozygous in the tumor tissue. Homo/hemizygosity of
the splice sitemutation inTH in the tumor cells may arise
from a double-strand break that happens close to the
mutation site on the wild-type chromosome and is re-
paired using the second chromosome (mutated). This
appears to be a common repair mechanism at G2 (7 ).
The event would be similar to the homologous recombi-
nation mechanism during meiosis and the same as gene
conversion, involving just a few hundred bp of the het-
eroduplex during the repair. This would explain the pres-
ence of one heterozygous SNP at approximately 2364 bp
downstream of the mutation (Fig. 1D). In other words,
the double-strand break and repair happened locally in
an early stage of tumor development. qPCR data demon-
strated that THmRNA expression for this tumor is only
5% of the level of all pheochromocytomas (n  50)
recorded in our database, suggesting that transcribed
mRNA from TH in the tumor is subsequently destroyed
by the nonsense-mediated mRNA decay (NMD) path-
way before being translated to TH protein, a phenome-
non usually observed in RNAs with a premature stop
codon (7, 8 ).
TH deficiency led to depressed concentrations of
L-Dopa and prevented the synthesis of the pharmacolog-
ically active catecholamines and their surrogate markers
metanephrines within the tumor. Interestingly, no clini-
cal signs suggestive of a sympathetic system default were
noticed in this patient despite the presence of only one
functional allele of TH for proper catecholamine synthe-
sis. Similarly, catecholamine synthesis is also normal in
heterozygous parents of children suffering from TH de-
ficiency, referred to as autosomal recessive Segawa dis-
ease; since it is a recessive disease, we expect an absence of
symptoms in heterozygote carriers as observed with this
patient, who exhibited resting catecholamine concentra-
tions in the normal range (9 ).
CASE FOLLOW-UP
This finding has proven that the concerns initially raised
regarding the relevance of measuring metanephrines for
the biochemical diagnosis of pheochromocytoma were
groundless. Fortunately, this missed pheochromocytoma
diagnosis had no other clinical consequences than the late
diagnosis of a large mass, since the tumor was not pro-
ducing catecholamines. Finally and most importantly, the
patient has fully recovered and, after a 24-month follow-up
CT scan, there is no evidence of recurrence. In conclusion,
TH mutation is a rare cause of nonsecreting pheochromo-
cytoma that should, however, not be ignored.
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POINTS TO REMEMBER
• Some histologically proven adrenal pheochromocyto-
mas are tumors that do not produce or secrete cat-
echolamines and metanephrines.
• If chromogranin A concentrations are found to be in-
creased initially, chromogranin A measurement might be
the test of choice to diagnose a recurrence in the follow-up
(although not performed in the present study).
• Adrenal incidentaloma must be investigated biochemi-
cally to assess/exclude a pheochromocytoma. Plasma or
urine metanephrines are the biochemical tests of choice.
In the present case genetic studies elucidated “this
exception to the rule” and reconciled the findings of
clinical chemists and pathologists.
• Metanephrine assays are unreliable to monitor a non-
catecholamine-secreting pheochromocytoma and imaging
studies must be considered for follow-up. If the tumor
described here were to relapse, it would be interesting to
see whether it still had the same somatic mutation.
• When a pheochromocytoma is clearly suspected, the pa-
tient must be meticulously prepared with -blocking
agents to prevent hypertensive crises during surgery and
fluid correction to prevent postsurgical hypotension.
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Commentary
Parmpreet Kaur1 and Ravinder J. Singh2*
The morbidity and mortality of pheochromocytomas are
mainly due to hypersecretion of catecholamines, which
results in various hypertensive crises. These tumors may
be identified by symptomatology or incidentally on ra-
diographs ordered for unrelated indications. Pheochro-
mocytoma is further confirmed by biochemical abnor-
malities and is then cured by surgical resection. The
current case illustrates that there are a few patients with
nonfunctional adrenal tumors (clinically considered
pheochromocytomas and resected by surgery) who do
not secrete excess amounts of catecholamines and have
no hypertensive symptoms. Such patients will not be de-
tected by the routine testing of catecholamines/meta-
nephrines. The synthesis of catecholamine is a complex
process and involves conversion of tyrosine to L-Dopa by
the enzyme TH. Tumors with mutations of tyrosine hy-
droxylase will not be able to complete the synthesis of
catecholamines. In such cases, anatomical pathologists
confirm the tumor using immune-histochemical, ultra-
structural, and local rare chemical properties of the tu-
mors in these patients. This may need further confirma-
tion by molecular genetics, using either the single
mutation or combination of the most common muta-
tions related to pheochromocytoma.Whole genome next
generation sequencing is becoming very popular; how-
ever, the technique may have the challenges of confirm-
ing whether a found mutation is benign or has any clin-
ical significance.
The Endocrine Society recommends succinate de-
hydrogenase gene testing for individuals with pheochro-
mocytomas. However, there are no specific guidelines for
TH genetic testing for pheochromocytomas, especially
for rare nonfunctional benign pheochromocytomas. This
case is a reminder that chemical or genetic laboratory tests
may never be 100% sensitive or specific, especially for
rare diseases. The ultimate care of patients with pheo-
chromocytomas will be the combined assessment of the
physicians, radiologists, pathologists, and surgeons
involved.
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